LY 3962681
Alternative Names: LY-3962681Latest Information Update: 16 Oct 2024
Price :
$50 *
At a glance
- Originator Prevail Therapeutics
- Class Antiparkinsonians; Gene therapies; Small interfering RNA
- Mechanism of Action Alpha-synuclein expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 27 Aug 2024 Phase-I clinical trials in Parkinson's disease in Japan (Intrathecal) (NCT06565195)
- 27 Aug 2024 Phase-I clinical trials in Parkinson's disease in USA (Intrathecal) (NCT06565195)
- 26 Aug 2024 Preclinical trials in Parkinson's disease in USA (Intrathecal)